Skip to main content

Advertisement

Table 2 Event numbers and hazard ratio of the primary outcome between the study cohorts

From: Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

Outcome Number of event (%) Statin vs. non-statin
Statin (n = 441) Non-statin (n = 441) HR (95% CI) P value
3 Month follow-up
 Non-fatal ischemic stroke 2 (.5) 5 (1.1) .40 (.08, 2.05) .271
 Non-fatal myocardial infarction 13 (2.9) 12 (2.7) 1.09 (.50, 2.38) .834
 Cardiovascular death 13 (2.9) 21 (4.8) .62 (.31, 1.24) .173
 Primary composite outcomea 27 (6.1) 37 (8.4) .73 (.44, 1.20) .211
6 Month follow-up
 Non-fatal ischemic stroke 6 (1.4) 8 (1.8) .73 (.25, 2.10) .559
 Non-fatal myocardial infarction 26 (5.9) 24 (5.4) 1.06 (.61, 1.85) .835
 Cardiovascular death 24 (5.4) 27 (6.1) .87 (.51, 1.52) .633
 Primary composite outcomea 52 (11.8) 56 (12.7) .91 (.62, 1.32) .610
1 year follow-up
 Non-fatal ischemic stroke 10 (2.3) 16 (3.6) .58 (.26, 1.27) .170
 Non-fatal myocardial infarction 40 (9.1) 33 (7.5) 1.16 (.73, 1.83) .541
 Cardiovascular death 33 (7.5) 37 (8.4) .85 (.53, 1.36) .506
 Primary composite outcomea 77 (17.5) 78 (17.7) .93 (.68, 1.28) .660
At the end of follow-up
 Non-fatal ischemic stroke 26 (5.9) 33 (7.5) .58 (.35, .98) .040
 Non-fatal myocardial infarction 69 (15.6) 45 (10.2) 1.32 (.91, 1.92) .149
 Cardiovascular death 63 (14.3) 51 (11.6) 1.00 (.69, 1.45) .982
 Primary composite outcomea 133 (30.2) 111 (25.2) .98 (.76, 1.27) .883
  1. CI confidence interval, HR hazard ratio
  2. aAnyone of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke